Carrolee Barlow, MD, PhD, is Chief Medical Officer for Arialys Therapeutics. Dr. Barlow is a renowned expert in neuroscience, neurodegeneration, and drug development for rare diseases. Prior to joining Arialys, Dr. Barlow was the Chief Medical Officer of ESCAPE Biosciences. Recently, Dr. Barlow served as a consultant and clinical advisor to several biotechnology companies developing small molecules and biologics for the treatment of rare diseases. Dr. Barlow’s previous work spanned clinical care, laboratory and clinical research, in both academia and industry. She is the former CEO of the Parkinson’s Institute and Clinical Center, an independent nonprofit organization providing research, clinical trials, and clinical care. Before joining the Parkinson’s Institute, Dr. Barlow was acting Chief Medical Officer at Amicus Therapeutics and also was a co-founder, Chief Scientific Officer, and Chief Medical Officer of BrainCells, Inc. Prior to BrainCells, she served as the Director of Molecular Neuroscience and Worldwide Therapeutic Area Head for Stroke and Neurodegeneration at Merck Research Laboratories, responsible for neuroscience biology, global exploratory, licensing and development efforts. She serves as an advisory board member and is on the Board of Directors of several biotechnology companies and disease foundations advancing therapies for rare diseases and disorders of the central nervous system. Earlier in her career, Dr. Barlow held a faculty position at the Laboratory of Genetics at the Salk Institute for Biological Studies in La Jolla, California. Dr. Barlow received her Doctor of Medicine from the University of Utah School of Medicine. In addition, she received her Doctor of Philosophy in Molecular and Developmental Biology from the Karolinska Medical Nobel Institute in Stockholm, Sweden. She is an author of approximately 100 peer-reviewed research papers and book chapters and is an inventor on numerous issued patents.